CCB International To Set Up First Health Care Industry Fund With RMB 5 Billion
This article was originally published in PharmAsia News
Executive Summary
CCB International, a wholly-owned subsidiary of China Construction Bank Corporation, recently revealed that it has been establishing a health care investment fund since November 2007. With a first phase investment not exceeding RMB 5 billion, the Tianjin-registered fund will be China's first private equity focusing on the health care industry, including pharmaceuticals, medical devices, medical institutions and health care services. The seven-year closed-end fund obtains capital from various undisclosed sources. CCB International will collaborate with well-known domestic and overseas health care management funds and groups to jointly manage the fund. According to survey, China has a total of 5,744 health care management organizations covering 23 provinces, four municipalities and four autonomous regions. (Click here for more - Chinese Language)
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.